Novo Nordisk has launched the first GLP-1 weight-loss pill in the United States.
The once-daily Wegovy pill costs significantly less than injectable alternatives.
It is currently the only pill on the market that mimics the GLP-1 hormone to reduce appetite.
Self-paying patients can access starting doses for $149 per month.
Injectable GLP-1 drugs often cost around $1,000 monthly in the US.
The pill is expected to attract patients seeking needle-free treatment options.
Novo aims to regain market share amid strong competition from Eli Lilly.
The drug is available through major pharmacies including CVS and Costco.
UK regulators are reviewing approval, with a decision expected later this year.
Novo Nordisk Launches Wegovy Pill in US, Intensifying Weight-Loss Drug Price War
Andrew Rogers
Andrew Rogers is a freelance journalist based in the USA, with over 10 years of experience covering Politics, World Affairs, Business, Health, Technology, Finance, Lifestyle, and Culture. He earned his degree in Journalism from the University of Florida. Throughout his career, he has contributed to outlets such as The New York Times, CNN, and Reuters. Known for his clear reporting and in-depth analysis, Andrew delivers accurate and timely news that keeps readers informed on both national and international developments.